Linked Life Data

19364934

Source:http://linkedlifedata.com/resource/pubmed/id/19364934

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2009-4-14
pubmed:abstractText
To report the long-term follow-up (mean, 41 months; range, 25-55 months) of patients with demyelinating neuropathy occurring after tumor necrosis factor-alpha (TNF-alpha) blocker treatment (infliximab [Remicade], etanercept [Enbrel], and adalimumab [Humira]).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1538-3687
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
66
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
490-7
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:19364934-Adult, pubmed-meshheading:19364934-Anti-Inflammatory Agents, pubmed-meshheading:19364934-Antibodies, Monoclonal, pubmed-meshheading:19364934-Antibodies, Monoclonal, Humanized, pubmed-meshheading:19364934-Arthritis, Psoriatic, pubmed-meshheading:19364934-Arthritis, Rheumatoid, pubmed-meshheading:19364934-Crohn Disease, pubmed-meshheading:19364934-Demyelinating Diseases, pubmed-meshheading:19364934-Drug Therapy, Combination, pubmed-meshheading:19364934-Female, pubmed-meshheading:19364934-Follow-Up Studies, pubmed-meshheading:19364934-Hidradenitis Suppurativa, pubmed-meshheading:19364934-Humans, pubmed-meshheading:19364934-Immunization, Passive, pubmed-meshheading:19364934-Immunoglobulin G, pubmed-meshheading:19364934-Immunosuppressive Agents, pubmed-meshheading:19364934-Lymphotoxin-alpha, pubmed-meshheading:19364934-Male, pubmed-meshheading:19364934-Middle Aged, pubmed-meshheading:19364934-Neurologic Examination, pubmed-meshheading:19364934-Plasma Exchange, pubmed-meshheading:19364934-Receptors, Tumor Necrosis Factor, pubmed-meshheading:19364934-Spondylitis, Ankylosing, pubmed-meshheading:19364934-Treatment Outcome
pubmed:year
2009
pubmed:articleTitle
Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.
pubmed:affiliation
Department of Neurology, Assistance Publique-Hôpitaux de Paris, Université Paris Sud, France. pierre.lozeron@bct.aphp.fr
pubmed:publicationType
Journal Article, Case Reports